Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia

Retinal gene therapy is increasingly recognized as a novel molecular intervention that has huge potential in treating common causes of blindness, the majority of which have a genetic aetiology1–5. Choroideremia is a chronic X-linked retinal degeneration that was first described in 18726. It leads to progressive blindness due to deficiency of Rab-escort protein 1 (REP1). We designed an adeno-associated viral vector to express REP1 and assessed it in a gene therapy clinical trial by subretinal injection in 14 patients with choroideremia. The primary endpoint was vision change in treated eyes 2 years after surgery compared to unoperated fellow eyes. Despite complications in two patients, visual acuity improved in the 14 treated eyes over controls (median 4.5 letter gain, versus 1.5 letter loss, P = 0.04), with 6 treated eyes gaining more than one line of vision (>5 letters). The results suggest that retinal gene therapy can sustain and improve visual acuity in a cohort of predominantly late-stage choroideremia patients in whom rapid visual acuity loss would ordinarily be predicted.The long-term follow-up results of a phase 1/2 retinal gene therapy clinical trial for choroideremia (NCT01461213) support the safety and efficacy of the treatment.

[1]  S. Shapiro,et al.  An Analysis of Variance Test for Normality (Complete Samples) , 1965 .

[2]  J. Bennett.  Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  R. MacLaren,et al.  Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina , 2016, Molecular therapy. Nucleic acids.

[4]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[5]  A. J. Roman,et al.  Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations. , 2006, Investigative ophthalmology & visual science.

[6]  J. Sahel,et al.  Clinical characteristics and current therapies for inherited retinal degenerations. , 2015, Cold Spring Harbor perspectives in medicine.

[7]  W. Hauswirth,et al.  A comprehensive review of retinal gene therapy. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Susan M. Downes,et al.  A Qualitative and Quantitative Assessment of Fundus Autofluorescence Patterns in Patients With Choroideremia , 2016, Investigative ophthalmology & visual science.

[9]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[10]  I. MacDonald,et al.  Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience. , 2018, American journal of ophthalmology.

[11]  Jennifer K. Sun,et al.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.

[12]  F. Cremers,et al.  Cloning of a gene that is rearranged in patients with choroideraemia , 1990, Nature.

[13]  R. MacLaren,et al.  Correlation of retinal structure and function in choroideremia carriers. , 2015, Ophthalmology.

[14]  M. Brown,et al.  Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. , 1993, Science.

[15]  L. Vandenberghe.  What Is Next for Retinal Gene Therapy? , 2015, Cold Spring Harbor perspectives in medicine.

[16]  U. Schmidt-Erfurth,et al.  The influence of cortical, nuclear, subcortical posterior, and mixed cataract on the results of microperimetry , 2011, Eye.

[17]  K. Xue,et al.  Technique of retinal gene therapy: delivery of viral vector into the subretinal space , 2017, Eye.

[18]  R. MacLaren,et al.  The Biological Activity of AAV Vectors for Choroideremia Gene Therapy Can Be Measured by In Vitro Prenylation of RAB6A , 2018, Molecular therapy. Methods & clinical development.

[19]  K. Xue,et al.  Correlation of Optical Coherence Tomography and Autofluorescence in the Outer Retina and Choroid of Patients With Choroideremia , 2016, Investigative ophthalmology & visual science.

[20]  W. Hauswirth,et al.  Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial , 2016, Human Genetics.

[21]  L. Reznicek,et al.  Structure-function relationship between Heidelberg Retina Tomography (HRT) and Heidelberg Edge Perimeter (HEP) parameters in glaucoma suspects , 2016 .

[22]  J. Bennett,et al.  Visual Psychophysics and Physiological Optics High-Resolution Adaptive Optics Retinal Imaging of Cellular Structure in Choroideremia , 2014 .

[23]  N. Bressler,et al.  Measurement and Reproducibility of Preserved Ellipsoid Zone Area and Preserved Retinal Pigment Epithelium Area in Eyes With Choroideremia. , 2017, American journal of ophthalmology.

[24]  R. MacLaren,et al.  Evaluation of an Optimized Injection System for Retinal Gene Therapy in Human Patients. , 2014, Human gene therapy methods.

[25]  A. V. Cideciyan,et al.  Visual Function and Central Retinal Structure in Choroideremia. , 2016, Investigative ophthalmology & visual science.

[26]  A. Farmery,et al.  First-in-human study of the safety and viability of intraocular robotic surgery , 2018, Nature Biomedical Engineering.

[27]  G. Holder,et al.  Visual Acuity after Retinal Gene Therapy for Choroideremia. , 2016, The New England journal of medicine.

[28]  Emily S. Charlson,et al.  Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study. , 2017, Ophthalmology.

[29]  K. Xue,et al.  Retinal Degeneration in Choroideremia follows an Exponential Decay Function. , 2018, Ophthalmology.

[30]  K. Xue,et al.  Structural and Functional Recovery Following Limited Iatrogenic Macular Detachment for Retinal Gene Therapy , 2017, JAMA ophthalmology.

[31]  Alexander Sumaroka,et al.  Vision 1 year after gene therapy for Leber's congenital amaurosis. , 2009, The New England journal of medicine.

[32]  F. Cremers,et al.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial , 2014, The Lancet.

[33]  T. Aleman,et al.  Macular pigment and lutein supplementation in choroideremia. , 2002, Experimental eye research.

[34]  R. MacLaren,et al.  Gene therapy for choroideremia using an adeno-associated viral (AAV) vector. , 2015, Cold Spring Harbor perspectives in medicine.

[35]  Michael J. Castle,et al.  Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey , 2011, Science Translational Medicine.

[36]  K. Xue,et al.  Characterizing the Natural History of Visual Function in Choroideremia Using Microperimetry and Multimodal Retinal Imaging , 2017, Investigative ophthalmology & visual science.